GLP-1 Agonists Linked to Lower Dementia Risk in Type 2 Diabetes Patients
Source – Medical News Today A recent study conducted by researchers at Karolinska Institutet in Sweden has revealed that GLP-1 agonists, a class of drugs used to treat type 2 diabetes, are associated with a decreased risk of developing dementia. Published in the journal eClinicalMedicine, this research underscores the potential cognitive benefits of GLP-1 agonists beyond their primary use in managing blood sugar levels and promoting weight loss. GLP-1 agonists, also known as GLP-1 analogs, have gained popularity for their multifaceted benefits in treating type 2 diabetes and obesity. These drugs not only aid in controlling blood sugar levels but also support weight loss and offer cardiovascular protection. Given that individuals with type 2 diabetes are at a higher risk of developing dementia, the study explored whether newer diabetes medications, such as GLP-1 agonists and DPP-4 inhibitors, might offer protective effects against cognitive decline. Study Design and Results The research...